PASG Passage BIO, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1787297 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY26.9%
TTM EPS YoY27.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-212.3%
ROA-69.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets99.8%
Debt / equity0.00x
Current ratio1.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.99x
Accruals ratio-0.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $23.28M | $40.18M |
| SG&A expense | $19.88M | $24.99M |
| Operating income | -$49.30M | -$70.40M |
| Income tax | $0 | $0 |
| Net income | -$45.52M | -$64.77M |
| EBITDA | -$48.57M | -$67.32M |
| EPS (basic) | -14.35 | -21.04 |
| EPS (diluted) | -14.35 | -21.04 |
| Weighted avg. shares (diluted) | 3.17M | 3.08M |
| Balance sheet | ||
| Cash & equivalents | $46.30M | $37.57M |
| Short-term investments | $0 | $39.18M |
| Current assets | $47.76M | $78.81M |
| PP&E, net | $4.11M | $9.33M |
| Total assets | $62.28M | $102.41M |
| Current liabilities | $23.08M | $19.36M |
| Total liabilities | $43.53M | $41.15M |
| Shareholders' equity | $18.75M | $61.26M |
| Shares outstanding | 3.18M | 3.16M |
| Cash flow statement | ||
| Operating cash flow | -$31.51M | -$47.96M |
| Capital expenditure | — | $34,000 |
| Free cash flow | — | -$47.99M |
| Investing cash flow | $40.22M | $54.95M |
| Financing cash flow | $23,000 | $8.87M |
| Depreciation & amortization | $728,000 | $3.08M |
| Stock-based compensation | $3.00M | $5.82M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.